2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2007101128v1 19/6/1065    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ritz, E. Articles by Wanner, C. Search for Related Content PubMed PubMed Citation Articles by Ritz, E. Articles by Wanner, C.

Lipid Abnormalities and Cardiovascular Risk in Renal Disease

Department of Internal Medicine, Division of Nephrology, University of Heidelberg, Heidelberg, Germany; and Department of Internal Medicine, Division of Nephrology, University of Würzburg, Würzburg, Germany

Correspondence: Dr. Eberhard Ritz, Nierenzentrum, Im Neuenheimer Feld 162, D-60120 Heidelberg, Germany. Phone: 49-6221-601705; Fax: 49-6221-603302; E-mail: prof.e.ritz{at}t-online.de

The recent 4D study failed to provide definitive evidence for benefit of statin use in type 2 diabetics on dialysis. This finding stands in stark contrast to a number of other observations in patients with early stages of chronic kidney disease where substantial benefit of statins had been documented. Here we discuss some potential explanations for the unexpected finding of the 4D study and for the negative association between below average total cholesterol and vascular mortality among dialysis patients. Admittedly, in the absence of definite evidence in dialysis patients, we still conclude that the administration of statins is appropriate in patients with manifest coronary disease.

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673